EA199900861A1 - Усеченные белки, родственные фактору роста эндотелия сосудов - Google Patents
Усеченные белки, родственные фактору роста эндотелия сосудовInfo
- Publication number
- EA199900861A1 EA199900861A1 EA199900861A EA199900861A EA199900861A1 EA 199900861 A1 EA199900861 A1 EA 199900861A1 EA 199900861 A EA199900861 A EA 199900861A EA 199900861 A EA199900861 A EA 199900861A EA 199900861 A1 EA199900861 A1 EA 199900861A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- truncated
- crp
- proteins
- growth factor
- tracked
- Prior art date
Links
- 239000003102 growth factor Substances 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 210000003038 endothelium Anatomy 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000003511 endothelial effect Effects 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000006444 vascular growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84298497A | 1997-04-25 | 1997-04-25 | |
| PCT/US1998/007801 WO1998049300A2 (en) | 1997-04-25 | 1998-04-20 | Truncated vegf-related proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA199900861A1 true EA199900861A1 (ru) | 2000-06-26 |
Family
ID=25288752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA199900861A EA199900861A1 (ru) | 1997-04-25 | 1998-04-20 | Усеченные белки, родственные фактору роста эндотелия сосудов |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0977854A2 (https=) |
| JP (1) | JP2001524828A (https=) |
| KR (1) | KR20010020259A (https=) |
| CN (2) | CN1260835A (https=) |
| AU (1) | AU7250298A (https=) |
| CA (1) | CA2287538A1 (https=) |
| EA (1) | EA199900861A1 (https=) |
| IL (1) | IL132537A0 (https=) |
| NZ (2) | NZ500530A (https=) |
| WO (1) | WO1998049300A2 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6734285B2 (en) | 1994-03-08 | 2004-05-11 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 proteins and compositions |
| US6040157A (en) | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| ES2249762T3 (es) | 1994-03-08 | 2006-04-01 | Human Genome Sciences, Inc. | Factor de crecimiento del endotelio vascular 2. |
| US5932540A (en) | 1994-03-08 | 1999-08-03 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| US7186688B1 (en) | 1994-03-08 | 2007-03-06 | Human Genome Sciences, Inc. | Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2 |
| US7153827B1 (en) | 1994-03-08 | 2006-12-26 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 and methods of use |
| US7109308B1 (en) | 1994-03-08 | 2006-09-19 | Human Genome Sciences, Inc. | Antibodies to human vascular endothelial growth factor 2 |
| US6608182B1 (en) | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
| US6783980B2 (en) | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US7423125B2 (en) | 1995-08-01 | 2008-09-09 | Vegenics Limited | Antibodies to VEGF-C |
| DE69628652T3 (de) | 1995-09-08 | 2012-05-03 | Genentech, Inc. | Vegf-verwandtes protein |
| US7125714B2 (en) | 1997-02-05 | 2006-10-24 | Licentia Ltd. | Progenitor cell materials and methods |
| CA2322748A1 (en) * | 1998-03-13 | 1999-09-16 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| EP1121143A2 (en) * | 1998-03-27 | 2001-08-08 | Dorothea J. Eicher | Vegf and vegf-c as infant formula supplements |
| DE19813774A1 (de) * | 1998-03-27 | 1999-09-30 | Max Planck Gesellschaft | Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF) |
| US6316603B1 (en) | 1998-09-08 | 2001-11-13 | Agouron Pharmaceuticals, Inc. | Modifications of the VEGF receptor-2 protein and methods of use |
| EP1126870B1 (en) * | 1998-10-26 | 2004-09-08 | Ludwig Institute For Cancer Research | Use of vegf-c or vegf-d gene or protein to prevent restenosis |
| EP1568375A1 (en) * | 1998-10-26 | 2005-08-31 | Ludwig Institute For Cancer Research | Use of VEGF-C or VEGF-D gene or protein to prevent restenosis |
| US6958147B1 (en) | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
| CA2348835A1 (en) | 1998-10-28 | 2000-05-04 | Cornell Research Foundation, Inc. | Methods for regulating angiogenesis and vascular integrity using trk receptor ligands |
| US6783953B1 (en) | 1998-12-22 | 2004-08-31 | Janssen Pharmaceutica N.V. | Vascular endothelial growth factor-X |
| US7223724B1 (en) | 1999-02-08 | 2007-05-29 | Human Genome Sciences, Inc. | Use of vascular endothelial growth factor to treat photoreceptor cells |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US7727971B2 (en) | 2000-02-04 | 2010-06-01 | Life Sciences Research Partners Vzw | Use of placental growth factor for treating ischemic muscle disease |
| AU4643501A (en) * | 2000-02-04 | 2001-08-14 | Flanders Interuniversity Institute For Biotechnology (Vib) | Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke |
| AU5523701A (en) | 2000-04-06 | 2001-10-23 | Wayne P Franco | Methods of using growth factors for treating heart disease |
| EP1157999A1 (en) * | 2000-05-24 | 2001-11-28 | Introgene B.V. | Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof |
| MXPA02003434A (es) | 2000-08-04 | 2002-09-02 | Human Genome Sciences Inc | Factor de crecimiento endotelial vascular 2. |
| WO2002014367A1 (fr) * | 2000-08-10 | 2002-02-21 | Center For Advanced Science And Technology Incubation,Ltd. | Facteur de croissance chimere de cellules endotheliales vasculaires de type humain |
| EP1191104A1 (en) * | 2000-09-26 | 2002-03-27 | Introgene B.V. | Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine |
| DE60138403D1 (de) | 2000-09-26 | 2009-05-28 | Crucell Holland Bv | Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten |
| AU2002228841C1 (en) | 2000-12-07 | 2006-11-23 | Sangamo Biosciences, Inc | Regulation of angiogenesis with zinc finger proteins |
| US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
| US7402312B2 (en) | 2001-04-13 | 2008-07-22 | Human Genome Sciences, Inc. | Antibodies to vascular endothelial growth factor 2 (VEGF-2) |
| CA2444632A1 (en) | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| NZ529915A (en) | 2001-06-20 | 2007-07-27 | Ludwig Inst Cancer Res | Stimulation of vascularization of ischemic tissue by angiogenesis with VEGF-B186 |
| NZ531733A (en) | 2001-10-15 | 2006-04-28 | Janssen Pharmaceutica Nv | Substituted 4-phenyl-4-[1H-imidazol-2-YL]- piperidine derivatives for reducing ischaemic damage |
| KR101021387B1 (ko) | 2002-04-25 | 2011-03-14 | 크루셀 홀란드 비.브이. | 아데노바이러스 벡터를 생산하기 위한 수단 및 방법 |
| EP1827494A4 (en) * | 2004-11-18 | 2010-02-17 | Wayne Franco | COMBINATION GROWTH THERAPY AND CELL THERAPY FOR THE TREATMENT OF ACUTE AND CHRONIC ORGANIC DISEASES |
| WO2010078624A1 (en) * | 2009-01-07 | 2010-07-15 | Vegenics Limited | Materials and methods for the treatment of hypertension |
| CN118546231B (zh) * | 2024-06-28 | 2026-01-30 | 温州医科大学 | 一种修复皮肤屏障的vegf改构蛋白及其在植物中表达的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1242149B (it) * | 1990-09-27 | 1994-02-16 | Consiglio Nazionale Ricerche | Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi |
| JPH08506008A (ja) * | 1992-11-18 | 1996-07-02 | アーチ ディベロプメント コーポレイション | 心筋及び血管平滑筋へのアデノウィルス介在遺伝子移入 |
| US6645933B1 (en) * | 1995-08-01 | 2003-11-11 | Helsinki University Licensing Ltd. Oy | Receptor ligand VEGF-C |
| WO1996026742A1 (en) * | 1995-02-28 | 1996-09-06 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
| US5928939A (en) * | 1995-03-01 | 1999-07-27 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b and dna coding therefor |
| NZ301611A (en) * | 1995-03-02 | 2000-02-28 | Amrad Operations Pty Ltd | a peptide having vascular endothelial growth factor like properties, nucleic acid molecule encoding it and its use |
| WO1996039421A1 (en) * | 1995-06-06 | 1996-12-12 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 3 |
-
1998
- 1998-04-20 EP EP98919794A patent/EP0977854A2/en not_active Withdrawn
- 1998-04-20 NZ NZ500530A patent/NZ500530A/en unknown
- 1998-04-20 CN CN98806232A patent/CN1260835A/zh active Pending
- 1998-04-20 JP JP54706298A patent/JP2001524828A/ja not_active Ceased
- 1998-04-20 EA EA199900861A patent/EA199900861A1/ru unknown
- 1998-04-20 WO PCT/US1998/007801 patent/WO1998049300A2/en not_active Ceased
- 1998-04-20 CN CNA200510009104XA patent/CN1680442A/zh active Pending
- 1998-04-20 IL IL13253798A patent/IL132537A0/xx unknown
- 1998-04-20 KR KR1019997009857A patent/KR20010020259A/ko not_active Ceased
- 1998-04-20 NZ NZ514872A patent/NZ514872A/en unknown
- 1998-04-20 AU AU72502/98A patent/AU7250298A/en not_active Abandoned
- 1998-04-20 CA CA002287538A patent/CA2287538A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0977854A2 (en) | 2000-02-09 |
| AU7250298A (en) | 1998-11-24 |
| WO1998049300A2 (en) | 1998-11-05 |
| IL132537A0 (en) | 2001-03-19 |
| NZ500530A (en) | 2001-12-21 |
| CN1260835A (zh) | 2000-07-19 |
| NZ514872A (en) | 2005-01-28 |
| KR20010020259A (ko) | 2001-03-15 |
| CA2287538A1 (en) | 1998-11-05 |
| WO1998049300A3 (en) | 1999-03-11 |
| JP2001524828A (ja) | 2001-12-04 |
| CN1680442A (zh) | 2005-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA199900861A1 (ru) | Усеченные белки, родственные фактору роста эндотелия сосудов | |
| AU1922101A (en) | Human fgf-21 gene and gene expression products | |
| EA200300845A1 (ru) | Модифицированные антитела и способы применения | |
| ATE83374T1 (de) | Neue galenische form von fenofibrat. | |
| DE69434538D1 (de) | Vaskularer endothelialer wachstumsfaktor 2 | |
| FI885543A0 (fi) | Dna-segment, polypeptider och anti-kroppar anslutande till human vaevnadsfaktor. | |
| DE3788961D1 (de) | Verfahren zur herstellung von polysubstituierten diethylentriaminpentaessigsäuren. | |
| ATE469654T1 (de) | Verwendung des erythropoietins zur regeneration von lebergewebe | |
| DE69433013D1 (de) | Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten | |
| ATE347910T1 (de) | Zusammensetzungen zur behandlung von ischamischem gewebe | |
| DE69836139D1 (de) | Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon | |
| DK0473724T3 (da) | Et humant cytokin, interleukin-9 | |
| MX172600B (es) | , "procedimiento para la produccion de una proteina biologicamente activa | |
| RU92016244A (ru) | Производные сахарина-ингибиторы протеолитических ферментов | |
| RU2649069C2 (ru) | Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1 | |
| WO1995028907A3 (en) | Megapoietin: a novel megakaryocyte growth promoting factor | |
| DE3268915D1 (en) | Angiotropins of leukocytes and inflamed tissue: a new class of natural chemotropic protein mitogens for specific induction of directional growth of blood vessels, neovascularization of tissues and morphogenesis of blood vessel patterns, process for their biotechnical preparation and pharmaceutical compositions | |
| RU94046426A (ru) | Фармацевтические композиции, способы лечения лейкоза, способ повышения уровней стволовых клеток, антагонист с - kit - лиганда, антисмысловая нуклеиновая кислота, способ лечения меланомы, способ усиления трансфекции, способ переноса гена, способ увеличения уровней периферической крови, способ повышения уровней тромбоцитов, способы модификации биологической функции, способ лечения анемии, способ улучшения приживления костного мозга, способ ускорения восстановления костного мозга, способ лечения лейкопении | |
| RU93005051A (ru) | Способ получения катионных кристаллов гр или производных гр, катионные кристаллы человеческого гр или производных человеческого гр, фармацевтические препараты, использование процесса кристаллизации | |
| BG49827A3 (bg) | Метод за получаване на пречистен биологично активен рекомбинантен човешки колоний стимулиращ фактор | |
| ATE363293T1 (de) | Injektion von autologem knochenmark in den herzmuskel | |
| EA200200533A1 (ru) | СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ СЕРДЕЧНО-СОСУДИСТОГО ЗАБОЛЕВАНИЯ ДОСТАВКОЙ ГЕНОВ in vivo | |
| ATE524542T1 (de) | Aus knochenmarksstützzellen stammende schwann'sche zellen | |
| BG101038A (bg) | Супресия на растежа на туморни клетки посредствомсиндекан- 1 ектоучастък | |
| EA199901002A1 (ru) | Методы и составы для лечения сердечной недостаточности и вентикулярной коррекции путем доставки in vivo ангиогенных трансгенов |